HIV vaccine development and the selection of neutralizing HIV Antibodies

The project aims to screen HIV envelope protein variants displayed proteins for catalytic activity using an “ad hoc” developed droplet-based microfluidic system.

In particular the trimeric surface envelope glycoprotein Env (gp120/gp41), which targets HIV-1 entry by interacting directly with cell CD4 receptor and co-receptors, will be the main targets. At first different gp120/gp41Env variants will be screened for stability of neutralizing epitopes and absence of non-neutralizing epitopes. HIV Env variants will be also evolved and screened using this system.

This program is funded by the International AIDS Vaccine Initiative